S100B and NSE serum levels in patients with Parkinson's disease
Authors:
- Adriano B.L. TortATAdriano B.L. Tort
- Daniele FrickeDFDaniele Fricke
- Pedro SchestatskyPSPedro Schestatsky
- Luis V.C. PortelaLPLuis V.C. Portela
- Diogo O. SouzaDSDiogo O. Souza
- Carlos R.M. RiederCRCarlos R.M. Rieder
- 1 January 2005
- journal article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 11 (1) , 39-43
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Expression of S‐100 protein is related to neuronal damage in MPTP‐treated miceGlia, 2003
- Pathogenic role of glial cells in Parkinson's diseaseMovement Disorders, 2002
- The role of glial cells in Parkinsonʼs diseaseCurrent Opinion in Neurology, 2001
- Increased serum S100B protein in schizophrenia: a study in medication-free patientsJournal of Psychiatric Research, 2001
- S100β Induces Neuronal Cell Death Through Nitric Oxide Release from AstrocytesJournal of Neurochemistry, 1997
- Human brain S100β and S100β mRNA expression increases with age: Pathogenic implications for Alzheimer's diseaseNeurobiology of Aging, 1996
- Neuron‐Specific Enolase Is Increased After Single Seizures During Inpatient Video/EEG MonitoringEpilepsia, 1996
- S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system.Stroke, 1987
- “Mini-mental state”Journal of Psychiatric Research, 1975
- ParkinsonismNeurology, 1967